Achillion Pharmaceuticals, Inc.

Bristol-myers Squibb Compnay

Other

Merck + Co., Inc.

Milind Deshpande

Avinash S Phadke

Dawei Chen

Jason Allan Wiles

Xiangzhu Wang

Akihiro Hashimoto

Qiuping Wang

Venkat Rao Gadhachanda

Godwin Pais

Atul Agarwal

William J Greenlee

Cuixian Liu

Shouming Li

Jesse Quinn

Andrew Y Thurkauf

Kyle J Eastman

Joel Charles Barrish

Barton James Bradbury

Edlaine Lucien

Suoming Zhang

Yiping Shen

Ha Young Kim

Junko Ohkanda

Michael Pucci

Owen Brendan Wallace

Akhiro Hashimoto

Godwin Clarence Gilroy Pais

Tao Wang

Zhongxing Zhang

Benito Munoz

Kap-Sun Yeung

Lawrence B Snyder

Michael H Serrano-Wu

Jeffrey Lee Romine

Xi Chen

Prasad V Chaturvedula

Scott W Martin

Michael Frederick Parker

Darren Whitehouse

Carl P Bergstrom

Haiquan Fang

David W Smith

Min Gao

Daniel J Keavy

Charles P Sloan

Julie A Lemm

Pin-Fang Lin

Michael F Summers

Donald R O'Boyle

Richard Colonno

Wade S Blair

Venkat Gadhachanada

Shouming Lee

Yongsheng Song

Kumar Srinivasan

Wai Yu Lau

Henry Hui Wang

Timothy P Spicer

Hui Wang

Micheal John Pucci

Atul Ararwal

Quinn Jesse

Liu Cuixian

Quiping Wang

Michael John Pucci

Godwin Clarence Pais

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I″ and I'″ or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein Ror Ron the A group is an aryl, heteroaryl or heterocycle (R) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Pharmaceutical compounds for treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I″ and I′″ or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I&#x2033; and I'&#x2033; or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Amide compounds for treatment of immune and inflammatory disorders

Amino compounds for treatment of immune and inflammatory disorders

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, or a pharmaceutically acceptable salt or composition thereof. The inhibitors of Factor D described herein reduce the excessive activation of complement, and are useful to treat disorders mediated by the complement system.

Disubstituted compounds for treatment of medical disorders

Growing community of inventors

Madison, CT, United States of America

Milind Deshpande